Credit score: Unsplash/CC0 Public Area
Breast most cancers survivors with extreme menopausal signs needs to be supported to make an knowledgeable determination about whether or not to have hormone alternative remedy or not, in keeping with an interdisciplinary panel of consultants together with researchers from UCL.
The research, printed in Menopause, gives essentially the most complete assessment so far on using hormone alternative remedy (HRT), often known as menopausal hormone remedy (MHT), in ladies who’ve been handled for breast most cancers. It brings collectively proof from medical trials, observational research, and professional opinion to deal with a long-standing medical dilemma: Can ladies safely use HRT to handle debilitating menopausal signs after breast most cancers?
Breast most cancers is the most typical most cancers amongst ladies worldwide, with 2.3 million ladies identified yearly. Trendy breast most cancers remedies are extremely efficient, so many ladies can count on to outlive long-term, with over 700,000 survivors within the UK alone. Many of those ladies expertise extreme menopausal signs as a facet impact of their most cancers remedy, or as a result of they expertise pure menopause however have restricted remedy choices after breast most cancers.
Whereas HRT is the simplest remedy for menopausal signs comparable to scorching flashes, insomnia, temper disturbances, and genitourinary signs (e.g. vaginal dryness, painful intercourse, recurrent urinary tract infections), its use has historically not been advisable in breast most cancers survivors as a result of it comprises estrogen, which might enhance the chance of illness recurrence in estrogen receptor-positive breast cancers, which account for 70–80% of breast cancers. NICE pointers due to this fact suggest that HRT is just utilized in” exceptional circumstances.”
The analysis gives new insights into the dangers and advantages of HRT for breast most cancers survivors and presents an Knowledgeable Consensus Assertion, a collective professional opinion that summarizes the very best accessible proof on a selected subject, calling for a extra patient-centered method to menopause care after breast most cancers.
Professor Jayant Vaidya, an writer of the research from UCL Surgical procedure & Interventional Science, mentioned, “Some of the profitable remedies for breast most cancers is to starve it of estrogen. Nevertheless, many breast most cancers survivors expertise menopausal signs that negatively affect their high quality of life. HRT that features estrogen is the simplest remedy for menopause signs, however it may enhance the chance of relapse in estrogen receptor-positive breast cancers, which could be stimulated to develop by estrogen. Consequently, in observe it’s hardly ever prescribed.
“Primarily based on our evaluation of the accessible proof, we predict that some ladies might contemplate it cheap to take HRT after breast most cancers, after recognizing their very own danger profile, if it meaningfully improves their high quality of life.
“What we really need now is a new clinical trial, such as the MENO-ABC trial that we’re proposing, to accurately quantify the risks and benefits in light of modern diagnostic methods and treatments, so that women and their clinicians have the complete information they need to make an informed decision.”
Reaching a consensus on what the very best accessible proof says
For the research, a panel of 25 consultants was assembled, together with 18 voting members (10 menopause specialists, 4 medical oncologists, three breast most cancers surgeons, and one radiologist) and 7 affected person representatives. Affected person representatives performed a key function in shaping the Knowledgeable Consensus Assertion to make sure that it displays real-world issues and priorities.
Collectively the panel created 38 statements summarizing the important thing points referring to HRT and breast most cancers.
With these statements in thoughts, the 18 medical panel members reviewed the accessible proof regarding use of each regionally efficient vaginal hormones (vaginal estrogen and vaginal dehydroepiandrosterone, DHEA) and systemic HRT (estrogen, progesterone, and testosterone, which have results all through the physique), in ladies with and with out a historical past of breast most cancers.
Throughout three voting rounds, the unique statements had been reviewed and edited till 34 consensus statements had been produced, with which at the least 70% of the panel agreed. Statements that didn’t obtain consensus had been rejected.
Among the many key conclusions had been:
Vaginal estrogen is unlikely to extend the chance of breast most cancers recurrence on account of minimal systemic absorption and can be utilized to deal with genitourinary signs in breast most cancers survivors.
Systemic HRT can enhance the chance of relapse in ladies with estrogen receptor (ER) optimistic breast most cancers, notably throughout the first 5–10 years after analysis. Nevertheless, solely a small proportion of this enhance in danger is for the extra harmful “distant relapse,” the place the most cancers spreads to a different a part of the physique. The magnitude of this enhance in danger is more likely to differ in keeping with the background danger of relapse, and a few sufferers with low-to-medium danger breast most cancers and extreme menopausal signs might select to simply accept a rise in danger and take HRT to enhance their high quality of life.
Shared decision-making is vital. All sufferers contemplating HRT needs to be supported to make knowledgeable selections based mostly on their signs, most cancers historical past, and private preferences.
The panel additionally advisable that sufferers contemplating HRT after breast most cancers needs to be enrolled in a medical trial, such because the proposed MENO-ABC trial, which goals to assemble long-term information on outcomes together with recurrence, mortality and high quality of life.
The proof on relapse danger
The authors reviewed the very best accessible randomized proof and located that within the normal inhabitants, 2.3% of ladies aged 50–59 develop breast most cancers over 5 years. Mixed estrogen and progestin HRT will increase the chance to 2.7%, however estrogen-only HRT decreases it to 1.9%.
The authors critically reviewed information from two randomized medical trials (HABITS and the Stockholm Examine) and located that in breast most cancers sufferers who had moderate-risk illness, HRT will increase the chance of relapse from 14% to twenty% over seven years. In different phrases, 80% of ladies who use HRT after medium-risk breast most cancers is not going to expertise a relapse.
For girls with low-risk breast most cancers, HRT will increase the chance of relapse from 5% to 7.2%. Which means that regardless of use of HRT, 92.8% of ladies with low-risk illness is not going to expertise a relapse.
Crucially, a lot of the enhance in danger from use of HRT is from native relapse or a second breast most cancers, which—whereas critical—is often totally treatable. The rise in danger of distant relapse, which is extra harmful and incurable, is comparatively small. For instance, HRT will increase the 7-year distant relapse price from 5.8% to six.3% in ladies with moderate-risk breast most cancers, and from 2.1% to 2.3% in ladies with low-risk illness.
Dr. Sarah Glynne, first writer of the research and a GP Menopause Specialist on the Portland Hospital, mentioned, “Ladies struggling with debilitating menopausal signs ought to be capable of speak to their clinicians and perceive the estimated danger to them personally in the event that they select to take HRT. It will allow ladies to correctly weigh up the professionals and cons of HRT—primarily aid from menopausal signs versus an elevated danger of relapse or second breast most cancers—and resolve for themselves whether or not they wish to take HRT or not.
“As a panel of experts, the consensus was that we should move away from a de facto ban of HRT after breast cancer diagnosis towards a more nuanced, evidence-based discussion that respects each woman’s circumstances, values and preferences.”
Extra info:
Sarah Glynne et al, Menopausal hormone remedy for breast most cancers sufferers: what’s the present proof?, Menopause (2025). DOI: 10.1097/GME.0000000000002627
Offered by
College School London
Quotation:
Specialists name for change of coronary heart on hormone alternative remedy after breast most cancers (2025, September 30)
retrieved 30 September 2025
from https://medicalxpress.com/information/2025-09-experts-heart-hormone-therapy-breast.html
This doc is topic to copyright. Other than any truthful dealing for the aim of personal research or analysis, no
half could also be reproduced with out the written permission. The content material is supplied for info functions solely.
